Skip to main content

Table 6 Economic analysis results in 2013 United States dollars for IPV5 compared to both reference cases (RCs) involving continued OPV use

From: An economic analysis of poliovirus risk management policy options for 2013–2052

Income level Discounted, cumulative vaccination costs ($ billions) Discounted, cumulative paralytic polio cases Incremental costs ($ billions) Paralytic polio cases prevented Incremental cost-effectiveness ratio (ICER) Incremental net benefits (INBs)
($ billions)
IPV5 Reference case IPV5 Reference case Per paralytic polio case prevented ($/case) Per DALY averted
($/DALY)
IPV5 vs. RC no SIAs and OPV restart without SIAs
LOW 2.9 3.9 2,700 420,00 −1.2 420,000 CLS CLS 4.7
LMI 6.1 7.4 3,700 350,00 −3.6 350,000 CLS CLS 15
UMI 12 8.1 150 1,200 3.7 1,000 3,600,000 250,000 −3.5
HIGH 16 15 3 8 0.4 5 80,000,000 5,600,000 −0.4
World 37 35 6,500 770,000 −0.6 770,000 N/A N/A 16
IPV5 vs. RC with SIAs and OPV restart with SIAs
LOW 2.9 8.9 1,400 1,500 −6.0 180 CLS CLS 6.0
LMI 6.1 18 2,400 2,400 −12 −48 CSLC CSLC 12
UMI 12 11 150 920 0.7 780 870,000 62,000 −0.5
HIGH 16 16 3 8 0.2 5 41,000,000 2,900,000 −0.2
World 37 53 3,900 4,800 −17 910 N/A N/A 17
  1. Abbreviations(see Table1for policy abbreviations): CLS, cost- and life-saving; CSLC, cost-saving but life-costing; DALY, disability-adjusted life-year; HIGH, high-income; ICER, incremental cost-effectiveness ratio; INBs, incremental net benefits; LMI, lower middle-income; LOW, low-income; N/A, not applicable; OPV, oral poliovirus vaccine; SIA, supplemental immunization activity; UMI, upper middle-income